He Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
He Yang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Changwei Yuan
Department of Purchasing Center, The First Affiliated Hospital of Henan University of Chinese Medicine , No. 19, Renmin Road , Zhengzhou , Henan, 450000 , P.R. China
1 shared publication - Chuanlei Zhang
Department of Purchasing Center, The First Affiliated Hospital of Henan University of Chinese Medicine , No. 19, Renmin Road , Zhengzhou , Henan, 450000 , P.R. China
1 shared publication - Lixia Yang
Department of Purchasing Center, The First Affiliated Hospital of Henan University of Chinese Medicine , No. 19, Renmin Road , Zhengzhou , Henan, 450000 , P.R. China
1 shared publication - Xiaoqi Chen
Department of Oncology, The First Affiliated Hospital of Henan University of Chinese Medicine
1 shared publication - Xinju Chen
Department of Spleen, Stomach, Liver, and Gallbladder, First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China
1 shared publication - Xinting Wang
Department of Purchasing Center, The First Affiliated Hospital of Henan University of Chinese Medicine , No. 19, Renmin Road , Zhengzhou , Henan, 450000 , P.R. China
1 shared publication
Latest Publications
- Open Access
- 27 September 2022
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 17 (1) , 1309-1314
One case of iodine-125 therapy – A new minimally invasive treatment of intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer associated with a poor prognosis. ICC accounts for about 10% of primary liver malignancies but with increasing incidence in recent years. Recently, some studies suggested that minimally interventional therapy can be used in the treatment of ICC. However, there are few references on interventional therapy for the clinical treatment of ICC. Herein we reported a case of a 48-year-old man who suffered from ICC. The patient was diagnosed with ICC by computerized tomography scan and pathological biopsy. The patient was completely cured by minimally interventional therapy with iodine-125 seed implantation. These results provide an important reference for the treatment option of ICC.
- 27 September 2022
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 17 (1) , 1309-1314
Open AccessOne case of iodine-125 therapy – A new minimally invasive treatment of intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer associated with a poor prognosis. ICC accounts for about 10% of primary liver malignancies but with increasing incidence in recent years. Recently, some studies suggested that minimally interventional therapy can be used in the treatment of ICC. However, there are few references on interventional therapy for the clinical treatment of ICC. Herein we reported a case of a 48-year-old man who suffered from ICC. The patient was diagnosed with ICC by computerized tomography scan and pathological biopsy. The patient was completely cured by minimally interventional therapy with iodine-125 seed implantation. These results provide an important reference for the treatment option of ICC.